Stay updated with breaking news from Valuating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosisData presented during poster and oral sessions at the 63rd American
WASHINGTON (dpa-AFX) - Centene Corporation (CNC) reaffirmed its 2021 total revenues guidance in the range of $125.2 billion to $126.4 billion and adjusted earnings per share guidance in the range
- Exploratory Analyses from the Pivotal HER2CLIMB Trial Show Patients with Stable and Active Brain Metastases Treated with a TUKYSA Regimen Maintained a Survival Benefit After Additional 15.6 Months
By Stephen Nakrosis Merck & Co. said Monday it would pause enrollment in Phase 3 clinical studies evaluating oral islatravir for pre-exposure prophylaxis in people at high risk of HIV-1... | December 7, 2021
WAKEFIELD, MA / ACCESSWIRE / December 7, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provides shareholders with perspectives on the